Venus Remedies Board Approves Financial Results & MOA Alterations

Venus Remedies Limited's Board of Directors met on July 20, 2026, to approve the unaudited financial results for the quarter ended June 30, 2026 (Consolidated and Standalone). The board also approved revisions to the proposed alteration of the Memorandum of Association (MOA) and Articles of Association (AOA). These revisions aim to align the Object Clause with the Companies Act, 2013, and update it with current and proposed business activities, while maintaining the company's primary operations in the pharmaceutical sector. The revised MOA will be presented to members for approval via a Special Resolution at the upcoming 37th Annual General Meeting. The trading window for designated persons was closed from July 1, 2026, until 48 hours after the financial results declaration.